Viking Therapeutics (VKTX) Stock Forecast & Price Target

$42.25 +0.76 (+1.83%)

(As of 12/20/2024 05:45 PM ET)

Viking Therapeutics - Analysts' Recommendations and Stock Price Forecast (2025)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Buy

Based on 13 Analyst Ratings

Sell
0

Hold
0

Buy
13

Based on 13 Wall Street analysts who have issued ratings for Viking Therapeutics in the last 12 months, the stock has a consensus rating of "Buy." Out of the 13 analysts, 11 have given a buy rating, and 2 have given a strong buy rating for VKTX.

Consensus Price Target

$106.75
152.66% Upside

According to the 13 analysts' twelve-month price targets for Viking Therapeutics, the average price target is $106.75. The highest price target for VKTX is $138.00, while the lowest price target for VKTX is $74.00. The average price target represents a forecasted upside of 152.66% from the current price of $42.25.

Get the Latest News and Ratings for VKTX and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Viking Therapeutics and its competitors.

VKTX Analyst Ratings Over Time

Type	Current Forecast 12/23/23 to 12/22/24	1 Month Ago 11/23/23 to 11/22/24	3 Months Ago 9/24/23 to 9/23/24	1 Year Ago 12/23/22 to 12/23/23
Strong Buy	2 Strong Buy rating(s)	2 Strong Buy rating(s)	1 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	11 Buy rating(s)	10 Buy rating(s)	10 Buy rating(s)	9 Buy rating(s)
Hold	0 Hold rating(s)	0 Hold rating(s)	0 Hold rating(s)	0 Hold rating(s)
Sell	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)
Consensus Price Target	$106.75	$109.73	$108.60	$30.25
Forecasted Upside	152.66% Upside	108.65% Upside	67.05% Upside	59.21% Upside
Consensus Rating	Buy	Buy	Buy	Buy

2025 could be “worse than the dot-com bust”, says man who predicted 2008 banking crisis (Ad)

Dan is sharing his latest work with the public. Because what he's tracking right now, he says, is too serious to keep private.

Click here to see Dan's full warning to the public.

VKTX Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

VKTX Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Viking Therapeutics Stock vs. The Competition

Type	Viking Therapeutics	Medical Companies	S&P 500
Consensus Rating Score	3.15	2.81	2.51
Consensus Rating	Buy	Moderate Buy	Moderate Buy
Predicted Upside	152.66% Upside	25,828.18% Upside	14.53% Upside
News Sentiment Rating	Neutral News See Recent VKTX News	Positive News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Analyst Name	Action	Rating	Price Target	Upside/Downside on Report Date
12/18/2024	HC Wainwright 2 of 5 stars		Reiterated Rating	Buy ➝ Buy	$102.00 ➝ $102.00	+140.74%
12/2/2024	Piper Sandler 2 of 5 stars	B. Amin Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight	$74.00	+39.78%
11/22/2024	B. Riley 4 of 5 stars		Initiated Coverage	Buy	$109.00	+110.65%
11/20/2024	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Outperform
9/25/2024	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Outperform ➝ Outperform	$138.00 ➝ $138.00	+113.42%
9/12/2024	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Overweight ➝ Overweight	$105.00 ➝ $105.00	+72.61%
Get the Latest News and Ratings for VKTX and Related Stocks Enter your email address below to receive the latest news and analysts' ratings for Viking Therapeutics and its competitors with MarketBeat's FREE daily newsletter.
9/11/2024	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Overweight	$80.00	+46.39%
7/25/2024	Raymond James Subscribe to MarketBeat All Access for the recommendation accuracy rating	S. Seedhouse Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Target	Strong-Buy ➝ Strong-Buy	$116.00 ➝ $118.00	+76.67%
6/17/2024	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Buy ➝ Buy	$120.00 ➝ $120.00	+135.71%
6/4/2024	Maxim Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Buy ➝ Buy	$120.00 ➝ $120.00	+117.08%
3/26/2024	BTIG Research Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Buy ➝ Buy	$100.00 ➝ $125.00	+47.58%
3/15/2024	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Buy ➝ Buy	$80.00	+23.36%
3/7/2024	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Buy	$110.00	+20.64%
5/30/2023	Roth Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	D. Dupuis Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy
3/29/2023	Roth Mkm Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Buy	$15.00 ➝ $19.00	+18.53%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Sunday at 02:28 PM ET.

VKTX Forecast - Frequently Asked Questions

: According to the research reports of 13 Wall Street equities research analysts, the average twelve-month stock price forecast for Viking Therapeutics is $106.75, with a high forecast of $138.00 and a low forecast of $74.00.
: 13 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Viking Therapeutics in the last year. There are currently 11 buy ratings and 2 strong buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" VKTX shares.
: According to analysts, Viking Therapeutics's stock has a predicted upside of 152.66% based on their 12-month stock forecasts.
: Over the previous 90 days, Viking Therapeutics's stock had 1 upgrade by analysts.
: Viking Therapeutics has been rated by research analysts at B. Riley, HC Wainwright, Oppenheimer, Piper Sandler, and William Blair in the past 90 days.
: Analysts like Viking Therapeutics more than other "medical" companies. The consensus rating for Viking Therapeutics is Buy while the average consensus rating for "medical" companies is Moderate Buy. Learn more on how VKTX compares to other companies.

Stock Forecasts and Research Tools

Related Companies

Today's Ratings

Top Rated Stocks

More Ratings Tools

2025 could be “worse than the dot-com bust”, says man who predicted 2008 banking crisis (Ad)

Dan is sharing his latest work with the public. Because what he's tracking right now, he says, is too serious to keep private.

Click here to see Dan's full warning to the public.

This page (NASDAQ:VKTX) was last updated on 12/22/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Viking Therapeutics (VKTX) Stock Forecast & Price Target